HER2 as a target in invasive urothelial carcinoma

Cancer Medicine

Volumn 4, Issue 6, 2015, Pages 844-852

  Bellmunt, Joaquim ^a,b   Werner, Lillian ^a   Bamias, Aristotle ^c   Fay, André P ^a   Park, Rachel S ^a   Riester, Markus ^a   Selvarajah, Shamini ^d   Barletta, Justine A ^d   Berman, David M ^e   de Muga, Silvia ^b   Salido, Marta ^b   Gallardo, Enrique ^f   Rojo, Federico ^b,g   Guancial, Elizabeth A ^a   Bambury, Richard ^h   Mullane, Stephanie A ^a   Choueiri, Toni K ^a   Loda, Massimo ^d   Stack, Edward ^d   Rosenberg, Jonathan ^a,h  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF ATHENS   (Greece)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HOSPITAL DE SABADELL   (Spain)

^g UAM)   (Spain)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ERBB2; Genomic alterations; HER2; Prognosis; Urothelial carcinomas

Indexed keywords

CISPLATIN; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; MESSENGER RNA; METHOTREXATE; PLATINUM DERIVATIVE; VINBLASTINE; ERBB2 PROTEIN, HUMAN;

3T3 CELL LINE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GREECE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; ONCOGENE NEU; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROTO ONCOGENE; SCORING SYSTEM; SPAIN; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR INVASION; CLINICAL TRIAL; COPY NUMBER VARIATION; GENETICS; METABOLISM; METASTASIS; MULTICENTER STUDY; MUTATION; OBSERVER VARIATION; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; NEOPLASM METASTASIS; OBSERVER VARIATION; RECEPTOR, ERBB-2; RNA, MESSENGER; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 85006181438     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.432     Document Type: Article

References (38)

1. Bellmunt, J., S. Albiol, C. Suarez, and J. Albanell . 2009. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit. Rev. Oncol. Hematol. 69:211-222.
2. Bang, Y. J. 2012. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J. Clin. Gastroenterol. 46:637-648.
3. Murphy, C. G., and P. G. Morris . 2012. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 23:765-776.
4. Sauter, G., J. Lee, J. M. S. Bartlett, D. J. Slamon, and M. F. Press . 2009. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27:1323-1333.
5. Bose, R., S. M. Kavuri, A. C. Searleman, W. Shen, D. Shen, D. C. Koboldt, et al. 2013. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3:224-237.
6. Ding, L., G. Getz, D. A. Wheeler, E. R. Mardis, M. D. McLellan, K. Cibulskis, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075.
7. Greulich, H., B. Kaplan, P. Mertins, T.-H. Chen, K. E. Tanaka, C.-H. Yun, et al. 2012. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc. Natl. Acad. Sci. USA 109:14476-14481.
8. Guo, G., X. Sun, C. Chen, S. Wu, P. Huang, Z. Li, et al. 2013. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 45:1459-1463.
9. Ross, J. S., K. Wang, L. M. Gay, R. N. Al-Rohil, T. Nazeer, C. E. Sheehan, et al. 2014. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin. Cancer Res. 20:68-75.
10. Caner, V., N. S. Turk, F. Duzcan, N. L. S. Tufan, E. C. Kelten, S. Zencir, et al. 2008. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol. Oncol. Res. 14:261-266.
11. Fleischmann, A., D. Rotzer, R. Seiler, U. E. Studer, and G. N. Thalmann . 2011. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur. Urol. 60:350-357.
12. Gandour-Edwards, R., P. N. Lara Jr., A. K. Folkins, J. M. LaSalle, L. Beckett, Y. Li, et al. 2002. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95:1009-1015.
13. Grivas, P. D., M. Day, and M. Hussain . 2011. Urothelial carcinomas: a focus on human epidermal receptors signaling. Am. J. Transl. Res. 3:362.
14. Laé, M., J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, and A. Vieillefond . 2010. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann. Oncol. 21:815-819.
15. Marin, A., E. Arranz, A. Sanchez, P. Aunon, and M. Baron . 2010. Role of anti-Her-2 therapy in bladder carcinoma. J. Cancer Res. Clin. Oncol. 136:1915-1920.
16. Olsson, H., I. M. Fyhr, P. Hultman, and S. Jahnson . 2012. HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand. J. Urol. Nephrol. 46:102-107.
17. Wester, K., A. Sjostrom, M. D. L. Torre, J. Carlsson, and P. U. MalmstrÃm . 2002. HER-2-a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol. 41:282-288.
18. Iyer, G., H. Al-Ahmadie, N. Schultz, A. J. Hanrahan, I. Ostrovnaya, A. V. Balar, et al. 2013. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. 31:3133-3140.
19. Coogan, C. L., C. R. Estrada, S. Kapur, and K. J. Bloom . 2004. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63:786-790.
20. Latif, Z., A. D. Watters, I. Dunn, K. Grigor, M. A. Underwood, and J. M. S. Bartlett . 2004. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur. J. Cancer 40:56-63.
21. Simonetti, S., R. Russo, G. Ciancia, V. Altieri, G. De Rosa, and L. Insabato . 2009. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int. J. Surg. Pathol. 17:198-205.
22. Allgayer, H., R. Babic, K. U. Gruetzner, A. Tarabichi, F. W. Schildberg, and M. M. Heiss . 2000. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol. 18:2201-2209.
23. Ross, J. S., and B. McKenna . 2001. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 19:554-568.
24. Shinohara, H., S. Morita, M. Kawai, A. Miyamoto, T. Sonoda, I. Pastan, et al. 2002. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J. Surg. Res. 102:169-177.
25. Bamias, A., A. Karadimou, S. Lampaki, G. Aravantinos, I. Xanthakis, C. Papandreou, et al. 2011. Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. J. Clin. Oncol. 29:4510.
26. Hammond, M. E., D. F. Hayes, and A. C. Wolff . 2011. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J. Clin. Oncol. 29:e458.
27. Gunia, S., S. Koch, O. W. Hakenberg, M. May, C. Kakies, and A. Erbersdobler . 2011. Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa. Am. J. Clin. Pathol. 136:881-888.
28. Sanchez-Carbayo, M., N. D. Socci, J. Lozano, F. Saint, and C. Cordon-Cardo . 2006. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24:778-789.
29. Wun-Jae, K., K. Eun-Jung, K. Seon-Kyu, K. Yong-June, H. Yun-Sok, J. Pildu, et al. 2013. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol. Cancer. 9:3.
30. Robinson, M. D., D. J. McCarthy, and G. K. Smyth . 2010. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139-140.
31. Greulich, H., T.-H. Chen, W. Feng, P. A. Jänne, J. V. Alvarez, M. Zappaterra, et al. 2005. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med. 2:e313.
32. Kancha, R. K., N. von Bubnoff, N. Bartosch, C. Peschel, R. A. Engh, and J. Duyster . 2011. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One 6:e26760.
33. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. 2012. Nature 490:61-70.
34. Ross, J. S., K. Wang, R. N. Al-Rohil, T. Nazeer, C. E. Sheehan, G. A. Otto, et al. 2014. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod. Pathol. 27:271-280.
35. Cancer Genome Atlas Research Network. 2014. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-322.
36. Gårdmark, T., M. Carringer, E. Beckman, and P.-U. Malmström . 2005. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder. Urology 66:527-530.
37. Hussain, M. H. A., G. R. MacVicar, D. P. Petrylak, R. L. Dunn, U. Vaishampayan, P. N. Lara, et al. 2007. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J. Clin. Oncol. 25:2218-2224.
38. Wulfing, C., J. P. Machiels, D. J. Richel, M. O. Grimm, U. Treiber, M. R. De Groot, et al. 2009. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115:2881-2890.